Koudouna, A.; Gkioka, A.I.; Gkiokas, A.; Tryfou, T.M.; Papadatou, M.; Alexandropoulos, A.; Bartzi, V.; Kafasi, N.; Kyrtsonis, M.-C.
Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy. Int. J. Mol. Sci. 2024, 25, 2862.
https://doi.org/10.3390/ijms25052862
AMA Style
Koudouna A, Gkioka AI, Gkiokas A, Tryfou TM, Papadatou M, Alexandropoulos A, Bartzi V, Kafasi N, Kyrtsonis M-C.
Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy. International Journal of Molecular Sciences. 2024; 25(5):2862.
https://doi.org/10.3390/ijms25052862
Chicago/Turabian Style
Koudouna, Aspasia, Annita Ioanna Gkioka, Alexandros Gkiokas, Thomai M. Tryfou, Mavra Papadatou, Alexandros Alexandropoulos, Vassiliki Bartzi, Nikolitsa Kafasi, and Marie-Christine Kyrtsonis.
2024. "Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy" International Journal of Molecular Sciences 25, no. 5: 2862.
https://doi.org/10.3390/ijms25052862
APA Style
Koudouna, A., Gkioka, A. I., Gkiokas, A., Tryfou, T. M., Papadatou, M., Alexandropoulos, A., Bartzi, V., Kafasi, N., & Kyrtsonis, M. -C.
(2024). Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy. International Journal of Molecular Sciences, 25(5), 2862.
https://doi.org/10.3390/ijms25052862
